标题
Osteoporosis Management in the Era of
COVID
‐19
作者
关键词
-
出版物
JOURNAL OF BONE AND MINERAL RESEARCH
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-05-14
DOI
10.1002/jbmr.4049
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains
- (2020) Judith Everts‐Graber et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial
- (2020) Andrew Grey et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Hematological findings and complications of COVID ‐19
- (2020) Evangelos Terpos et al. AMERICAN JOURNAL OF HEMATOLOGY
- The Untold Toll — The Pandemic’s Effects on Patients without Covid-19
- (2020) Lisa Rosenbaum NEW ENGLAND JOURNAL OF MEDICINE
- Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports
- (2019) O. Lamy et al. OSTEOPOROSIS INTERNATIONAL
- Denosumab vs risedronate in glucocorticoid-induced osteoporosis: final results of a 24-month randomized, double-blind, double-dummy trial
- (2019) Kenneth G. Saag et al. Arthritis & Rheumatology
- Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐year Clinical Trial
- (2019) Athanasios D. Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
- (2019) Benjamin Z Leder et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors
- (2019) Elena Gonzalez-Rodriguez et al. BREAST CANCER RESEARCH AND TREATMENT
- Bone Mineral Density After Transitioning From Denosumab to Alendronate
- (2019) David Kendler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
- (2019) D.L. Kendler et al. OSTEOPOROSIS INTERNATIONAL
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
- (2019) Robert Coleman et al. LANCET ONCOLOGY
- Screening for Osteoporosis to Prevent Fractures
- (2018) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
- (2018) Michael R McClung et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Fracture Prevention with Zoledronate in Older Women with Osteopenia
- (2018) Ian R. Reid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women
- (2018) Felicia Cosman et al. BONE
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
- (2017) Steven R Cummings et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
- (2017) Arthur N. Lau et al. JOURNAL OF RHEUMATOLOGY
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
- (2017) Bente L Langdahl et al. LANCET
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- (2017) Kenneth G. Saag et al. NEW ENGLAND JOURNAL OF MEDICINE
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
- (2017) Henry G Bone et al. Lancet Diabetes & Endocrinology
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis
- (2016) Felicia Cosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate
- (2015) Felicia Cosman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
- (2015) Benjamin Z Leder et al. LANCET
- Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
- (2015) Alison T. Stopeck et al. SUPPORTIVE CARE IN CANCER
- Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab
- (2015) Jeffrey R. Curtis et al. Arthritis & Rheumatology
- Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial
- (2012) Andrew Grey et al. BONE
- A single-dose study of denosumab in patients with various degrees of renal impairment
- (2012) Geoffrey A Block et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The Adverse Effects of Estrogen and Selective Estrogen Receptor Modulators on Hemostasis and Thrombosis
- (2012) Arturo Artero et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
- (2011) Dennis M Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover
- (2011) Richard Eastell et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
- (2011) N. Freemantle et al. OSTEOPOROSIS INTERNATIONAL
- Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial
- (2010) Ann V Schwartz et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial
- (2010) Paul D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- FRAX® and its applications to clinical practice
- (2009) John A. Kanis et al. BONE
- Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
- (2009) Felicia Cosman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis
- (2009) Benjamin Z. Leder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolutionin vitro
- (2007) Zachary J. Henneman et al. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
- Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis
- (2007) Steven Boonen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started